In vitro cytotoxicity assay
In vitro cytotoxicities for leukemic cells towards serial dilutions of L-Asparaginase (0.003-10 IU/mL, Paronal, Christiaens, Breda, The Netherlands), prednisolone (0.08-250 µg/mL, BUFA BV, Uitgeest, the Netherlands), vincristine (0.05-50 µg/mL TEVA Pharma BV, Mijdrecht, The Netherlands), daunorubicin hydrochloride (0.002-2.0 µg/mL, Ceubidine, Rhône-Poulenc Rorer, Amstelveen, The Netherlands) or cytarabine (0.002-2.5 µg/mL, Cytosar, Pharmacia & Upjohn, Woerden, the Netherlands) were determined using the MTT assay.(4) Briefly, 1.6x10 5 leukemic cells (>90% purity as determined by morphological examination of MayGrunwald-Giemsa (Merck, Darmstadt, Germany) stained cytospin slides) were exposed to serial dilutions of chemotherapeutic drugs in duplicate in a final volume of 100 µL culture media (RPMI 1640 (Life Technologies, Breda, The Netherlands) supplemented with 10% fetal calfs serum (Integro, Zaandam, The Netherlands), 5 µg/mL transferrin, 5 ng/mL sodium selenite (ITS media supplement, Sigma-Aldrich, Zwijndrecht, The Netherlands), 100 IU/mL penicellin, 100 µg/mL streptomycin, 0.125 µg/mL fungizone (Life technologies)). Following 4 days of incubation in a humified incubator at 37 o C with 5% CO 2 , 5 mg/mL MTT (3-[4,5-dimethyldiazol-2-yl]-2,5-diphenyltetrazoliumbromide, Sigma-Aldrich) was added and incubated for an additional 6 hrs at 37 o C to facilitate reduction of MTT tetrazolium salt into formazan crystals by viable cells. Total formazan production was measured spectrophotometrically at 562 nm. For each patient sample, leukemic cells incubated in the absence of drugs was used as control, whereas the assay performed on pure media containing wells were used for background correction (blank values). Leukemic cells survival following exposure to each drug concentration was calculated for background corrected OD values using the formula: ((OD drug incubated wells / OD control wells) x 100%), and the LC50 drug concentrations, at which 50% of the leukemic cells die, were calculated.
Microarray expression analyses
RNA integrity testing, copy-DNA and copy-copy RNA (ccRNA) syntheses, washing, hybridization to Human Genome U133 plus 2.0 microarrays (Affymetrix, Santa Clara, CA), extraction of probe set intensities from CEL-files and normalization with RMA or VSN methods were performed as previously described. (1) Geneset enrichment analysis (GSEA; (5)) was performed on our Affymetrix U133 plus 2.0 microarray expression dataset for 117 T-ALL cases(6) using 1000 random permutations .
Enrichment scores and nominal p-values were obtained for up-or down-regulated probe sets among the TOP100, 200 or 500 most significantly, differentially expressed probesets for human ETP-ALL compared to other T-ALL cases. (7) Also up-or down-regulated genes or probesets for C/EBPA-mutated AML(8) and early T-cell (MPP-ETP-DN2A) and commited Tcell (DN2B-and later) subsets(9) were tested.
ETP-ALL patients were identified by Prediction Analysis of Microarrays (PAM) (10)
implemented in R (11) using the human ETP-ALL probe set signature. (7) The classifier was built on the 100, 200 or 500 most significant probe sets from this ETP-ALL gene signature (Supplementary Table S1 ) (7) using class labels immature cluster (n=15) and non-immature cluster (n-102) in our gene expression cohort comprising 117 T-ALL patient samples.
Patients with a cross-validated probability greater than 0.6 for being classified as immature were considered to be ETP-ALL patients. Microarray data are available at the gene expression omnibus (http://www.ncbi.nlm.nih.gov/geo/), accession GSE10609 and GSE26713.
Differentially expressed genes between ETP-ALL cases with or without bi-allelic TRG@ rearrangements (ABD versus non-ABD ETP-ALL) were obtained by regression analysis using the limma package in the R statistical software package.(11) VSN-or RMAnormalized expression values for MEF2C (probe set 239966_at), LMO1 (probe set 206718_at), LMO2 (probe set 204249_s_at), LYL1 (probe set 210044_s_at), ERG1
(probeset 1563392_at) and BAALC (probe set 222780_s_at) were used to test for differential expression between the T-ALL groups (representative probe sets were used).
Human hematopoietic progenitor signature genes (probesets) as established by
Novershtern and coworkers(12) within the immature cluster gene signature were enriched using the Fisher's exact test. Differentially expressed genes between the immature cluster (n=15) (13) versus other T-ALL cases (n=102) in our T-ALL microarray expression set were analyzed using the Wilcoxon statistical test and corrected for multiple testing error using the false discovery rate procedure as previously described(14) using the Bioconductor package Multitest. A total of 784 probesets with an FDR p-value less than p=0.01 was selected as the immature cluster expression signature gene set (Supplementary Table S5 ). 
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In vitro sensitivity of Immature cluster/ETP-ALLleukemic cells towards chemotherapeutic agents. In vitro drug sensitivity levels towards prednisolone (squares), vincristine (downside-facing triangles), daunorubicin (circles), Lasparaginase (upside-facing triangles) and cytarabine (diamonds) were measured for leukemic cells of Immature cluster/ETP-ALL patients (open symbols) versus other T-ALL cases (closed gray symbols). The sensitivity level for each sample is indicated as the LC50 drug concentration that is lethal for 50 percent of the leukemic cells. Significance levels have been indicated. NS, not significant. 
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